array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(26) "Bio-RAD Laboratories, Inc."
["slug"]=>
string(33) "001cd-us-bio-rad-laboratories-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920"
["description"]=>
string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics"
["address_street"]=>
string(20) "1000 Alfred Nobel Dr"
["address_place"]=>
string(8) "Hercules"
["address_region"]=>
string(10) "California"
["founding_date"]=>
string(10) "1952-02-08"
["website_domain"]=>
string(11) "bio-rad.com"
["website_url"]=>
string(23) "https://www.bio-rad.com"
["industry_codes"]=>
array(3) {
[0]=>
string(42) "In Vitro and In Vivo Diagnostic Substances"
[1]=>
string(33) "Laboratory Analytical Instruments"
[2]=>
string(47) "Electromedical and Electrotherapeutic Apparatus"
}
["employee_count"]=>
int(7900)
["article_count"]=>
int(661)
}
["articles"]=>
array(8) {
[0]=>
array(7) {
["title_en"]=>
string(86) "Bio-Rad Laboratories (NYSE:BIO) Price Target Lowered to $550.00 at Credit Suisse Group"
["snippet_en"]=>
string(283) "Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price objective reduced by Credit Suisse Group from $580.00 to $550.00 in a research note released on Friday, MarketBeat reports. Credit Suisse Group currently has an outperform rating on the medical research company’s stock."
["url"]=>
string(126) "http://www.defenseworld.net/2023/08/08/bio-rad-laboratories-nysebio-price-target-lowered-to-550-00-at-credit-suisse-group.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/50c72367-3fea-4f09-a983-dedc3af37019"
["source"]=>
string(16) "defenseworld.net"
["publication_date"]=>
string(10) "2023-08-08"
["categories"]=>
array(4) {
[0]=>
string(13) "Credit Rating"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(21) "Competitive Behaviour"
[3]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(56) "Procalcitonin tests market in Brazil: market size trends"
["snippet_en"]=>
string(93) "According to GlobalData, the procalcitonin tests market in Brazil was valued at 10.60 in 2022"
["url"]=>
string(91) "https://www.medicaldevice-network.com/data-insights/procalcitonin-tests-brazil-market-size/"
["image_url"]=>
NULL
["source"]=>
string(25) "medicaldevice-network.com"
["publication_date"]=>
string(10) "2023-08-03"
["categories"]=>
array(5) {
[0]=>
string(15) "Market Movement"
[1]=>
string(10) "New Market"
[2]=>
string(5) "R & D"
[3]=>
string(11) "Competition"
[4]=>
string(21) "Competitive Behaviour"
}
}
[2]=>
array(7) {
["title_en"]=>
string(52) "Diabetes assays market in Mexico: market size trends"
["snippet_en"]=>
string(89) "According to GlobalData, the diabetes assays market in Mexico was valued at 38.60 in 2022"
["url"]=>
string(87) "https://www.medicaldevice-network.com/uncategorized/diabetes-assays-mexico-market-size/"
["image_url"]=>
NULL
["source"]=>
string(25) "medicaldevice-network.com"
["publication_date"]=>
string(10) "2023-07-28"
["categories"]=>
array(5) {
[0]=>
string(15) "Market Movement"
[1]=>
string(10) "New Market"
[2]=>
string(5) "R & D"
[3]=>
string(11) "Competition"
[4]=>
string(21) "Competitive Behaviour"
}
}
[3]=>
array(7) {
["title_en"]=>
string(48) "Bio-Rad and Qiagen in Merger Talks? | CHEManager"
["snippet_en"]=>
string(244) "News
Bio-Rad and Qiagen in Merger Talks? 12.10.2022- Bio-Rad Laboratories is in talks to merge with fellow life-sciences company Qiagen in a deal that could be worth more than$ 10 billion, US business newspaper Wall Street Journal has reported,"
["url"]=>
string(73) "https://www.chemanager-online.com/en/news/bio-rad-and-qiagen-merger-talks"
["image_url"]=>
NULL
["source"]=>
string(21) "chemanager-online.com"
["publication_date"]=>
string(10) "2022-10-12"
["categories"]=>
array(3) {
[0]=>
string(25) "Business Model Resilience"
[1]=>
string(6) "Merger"
[2]=>
string(21) "Competitive Behaviour"
}
}
[4]=>
array(7) {
["title_en"]=>
string(71) "Bio-Rad, Harvard settle DNA analysis patent dispute with French company"
["snippet_en"]=>
string(206) "Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing."
["url"]=>
string(126) "https://www.reuters.com/legal/transactional/bio-rad-harvard-settle-dna-analysis-patent-dispute-with-french-company-2021-07-08/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3b60c69a-bc98-4e16-8fcd-86222fa59002"
["source"]=>
string(11) "reuters.com"
["publication_date"]=>
string(10) "2021-07-08"
["categories"]=>
array(9) {
[0]=>
string(16) "Case Settlements"
[1]=>
string(27) "Business Model & Innovation"
[2]=>
string(10) "Litigation"
[3]=>
string(17) "Business Disputes"
[4]=>
string(21) "Intellectual Property"
[5]=>
string(8) "Verdicts"
[6]=>
string(46) "Management of Legal and Regulatory Environment"
[7]=>
string(5) "Legal"
[8]=>
string(21) "Competitive Behaviour"
}
}
[5]=>
array(7) {
["title_en"]=>
string(55) "BIO Stock Price, Forecast & News (Bio-Rad Laboratories)"
["snippet_en"]=>
string(173) "Researching Bio-Rad Laboratories (NYSE:BIO) stock? View BIO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat."
["url"]=>
string(43) "https://www.marketbeat.com/stocks/NYSE/BIO/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/69688266-5bcb-4eab-a8e0-f2a6fe10ebd2"
["source"]=>
string(14) "marketbeat.com"
["publication_date"]=>
string(10) "2020-04-06"
["categories"]=>
array(4) {
[0]=>
string(11) "Regulations"
[1]=>
string(12) "Stock Market"
[2]=>
string(15) "Insider Trading"
[3]=>
string(21) "Competitive Behaviour"
}
}
[6]=>
array(7) {
["title_en"]=>
string(66) "Bio-Rad Laboratories, SmartHeat: Biggest Price Gainers (BIO, HEAT)"
["snippet_en"]=>
string(43) "Markets Data Center: Biggest Price Gainers."
["url"]=>
string(68) "https://wsj.com/articles/SB10001424052702303816504577321731748943756"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/282db971-cbda-4baf-8f9b-2537a0ed516c"
["source"]=>
string(7) "wsj.com"
["publication_date"]=>
string(10) "2012-04-03"
["categories"]=>
array(1) {
[0]=>
string(21) "Competitive Behaviour"
}
}
[7]=>
array(7) {
["title_en"]=>
string(74) "GE Healthcare and Bio-Rad reach settlement in label-free detection lawsuit"
["snippet_en"]=>
string(289) "Chalfont St.Giles, UK, August 13th, 2011 – GE Healthcare, a unit of General Electric Company (NYSE:GE) announced today that a settlement has been reached with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) in an intellectual property lawsuit related to GE Healthcare Life Sciences’..."
["url"]=>
string(121) "https://www.manufacturing.net/home/news/13084865/ge-healthcare-and-biorad-reach-settlement-in-labelfree-detection-lawsuit"
["image_url"]=>
NULL
["source"]=>
string(17) "manufacturing.net"
["publication_date"]=>
string(10) "2011-08-13"
["categories"]=>
array(5) {
[0]=>
string(16) "Case Settlements"
[1]=>
string(10) "Litigation"
[2]=>
string(21) "Intellectual Property"
[3]=>
string(5) "Legal"
[4]=>
string(21) "Competitive Behaviour"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(66)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(51)
}
[2]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(31)
}
[3]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(28)
}
[4]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(26)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(24)
}
[6]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(23)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(20)
}
[8]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(19)
}
[9]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(19)
}
[10]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(19)
}
[11]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(18)
}
[12]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(14)
}
[13]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(14)
}
[14]=>
array(2) {
["name"]=>
string(18) "Ecological Impacts"
["count"]=>
int(13)
}
[15]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(13)
}
[16]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(10) "New Market"
["count"]=>
int(9)
}
[19]=>
array(2) {
["name"]=>
string(11) "Regulations"
["count"]=>
int(9)
}
[20]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(8)
}
[21]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(7)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(7)
}
[23]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(7)
}
[24]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(7)
}
[25]=>
array(2) {
["name"]=>
string(16) "Case Settlements"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(13) "Credit Rating"
["count"]=>
int(5)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(5)
}
[28]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(5)
}
[29]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(5)
}
}
}
001cd-us-bio-rad-laboratories-inc
Bio-RAD Laboratories, Inc.
Location
California
Founded
1952-02-08
Website
https://www.bio-rad.com
Articles
661 Articles
Category
In Vitro and In Vivo Diagnostic Substances
Laboratory Analytical Instruments
Electromedical and Electrotherapeutic Apparatus
Description
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics
Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price objective reduced by Credit Suisse Group from $580.00 to $550.00 in a research note released on Friday, MarketBeat reports. Credit Suisse Group currently has an outperform rating on the medical research company’s stock.
News
Bio-Rad and Qiagen in Merger Talks? 12.10.2022- Bio-Rad Laboratories is in talks to merge with fellow life-sciences company Qiagen in a deal that could be worth more than$ 10 billion, US business newspaper Wall Street Journal has reported,
Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
Chalfont St.Giles, UK, August 13th, 2011 – GE Healthcare, a unit of General Electric Company (NYSE:GE) announced today that a settlement has been reached with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) in an intellectual property lawsuit related to GE Healthcare Life Sciences’...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
